Healthcare-focused investment firm Perceptive Advisors significantly increased its position in Corcept Therapeutics (CORT) during the second quarter of 2026, according to a recent SEC filing. The firm added approximately 348,000 shares, a nearly 700% increase, bringing its total holding to over 398,000 shares valued at $34.64 million as of June 30. This trade marks a substantial boost in Perceptive's conviction in the commercial-stage pharmaceutical company.
Investors should note that 13F filings are disclosed with a delay, revealing trades that occurred in the previous quarter. Corcept recently raised its full-year revenue guidance and is awaiting an FDA decision on its drug relacorilant for Cushing's syndrome, expected by December 2026.